Panvac-VF (falimarev/inalimarev) / Bavarian Nordic 
Welcome,         Profile    Billing    Logout  
 24 Diseases   3 Trials   3 Trials   144 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
NCT04491955: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Completed
2
32
US
CV301, MSB0011359C, N-803, NHS-IL12
National Cancer Institute (NCI)
Small Bowel Cancers, Colorectal Cancers
10/22
08/24
HCRN GI16-288, NCT03547999: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Checkmark Study of CV301 + nivolumab in CRC
Jul 2018 - Jul 2018: Study of CV301 + nivolumab in CRC
Active, not recruiting
2
78
US
mFOLFOX6, MVA-BN-CV301, Modified Vaccinia Ankara, CV301, FPV-CV301, Fowl Pox Virus, Nivolumab, Opdivo
Patrick Boland, Bavarian Nordic, Hoosier Cancer Research Network, Bristol-Myers Squibb
Metastatic Colorectal Cancer
03/24
12/24
NCT03315871: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Active, not recruiting
2
40
US
PROSTVAC-V, PROSTVAC-F, MSB0011359C (M7824), CV301
National Cancer Institute (NCI)
Prostate Cancer
01/25
01/25
NCT03376659: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Checkmark Study of CV301 + durvalumab in CRC & pancreatic cancer
Nov 2018 - Nov 2018: Study of CV301 + durvalumab in CRC & pancreatic cancer
Terminated
1/2
8
US
Durvalumab, MEDI4736, CV301, Capecitabine, Xeloda, Bevacizumab, Avastin
Georgetown University, Mayo Clinic, Indiana University, Emory University, National Cancer Institute (NCI), George Mason University, Thomas Jefferson University, MedImmune LLC, Bavarian Nordic
Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
08/21
08/23
NCT04574583: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Completed
1/2
12
US
SX-682, M7824, BinTrafusp Alfa, MVA-BN-CV301, modified vaccinia Ankara (MVA)-BN-CV301, recombinant fowlpox viral (FPV)-CV301
National Cancer Institute (NCI)
Metastatic Cancer, Solid Tumors
02/23
05/23
NCT00669734: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Active, not recruiting
1
18
US
Falimarev, fCEA-MUC-1-TRI, Fowlpox-CEA(D609)-MUC1(L93)-TRICOM Vaccine, Fowlpox-CEA-MUC-1-TRICOM, PANVAC-F, recombinant fowlpox-CEA-MUC-1-TRICOM vaccine, rFowlpox-CEA(D609)/MUC1(L93)/TRICOM Vaccine, Inalimarev, PANVAC-V, recombinant vaccinia-CEA-MUC-1-TRICOM vaccine, rVaccinia-CEA(D609)/MUC1(L93)/TRICOM Vaccine, Vaccinia-CEA-MUC1-TRICOM Vaccine, Laboratory Biomarker Analysis, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
09/21
04/25

Download Options